ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 16 of 75 for:    PEELING SKIN SYNDROME

Validation of the French Adaptation of the RAADS-R Scale : Scale of Asperger Syndrome Diagnosis (RAADS-R)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02826148
Recruitment Status : Completed
First Posted : July 7, 2016
Last Update Posted : July 7, 2016
Sponsor:
Collaborator:
Fondation Orange
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:
The diagnosis of developmental disorders in adults is still difficult. Indeed, in France, there is not questionnaires to easily and accurately diagnose this disorder. Several diagnostic scales were developed in English. Among them, RAADS-R scale, which is a clinical tool that aims to better identify autism spectrum disorders including mild forms in adult people and help to diagnose of high-functioning autism . The objective of this study is to perform a complete validation of this scale in the french version.

Condition or disease Intervention/treatment Phase
Autism Spectrum Disorder Other: RAADS-R scale Not Applicable

Detailed Description:
The diagnosis of developmental disorders in adults is still difficult. Indeed, in France, there is not questionnaires to easily and accurately diagnose this disorder. Several diagnostic scales were developed in English. Among them, RAADS-R scale, which is a clinical tool that aims to better identify autism spectrum disorders including mild forms in adult people and help to diagnose of high-functioning autism . This scale is a self-administered questionnaire completed by the person himself assisted by a clinician (psychiatrist, psychologist) which ensures the understanding of issues and the choice of answers. The scale contains 80 items including 64 questions describe specific symptoms of autism spectrum disorders and 16 questions describe non-symptomatic behaviors. The objective of this study is to perform a complete validation of this scale in the french version. 300 adults should be included, including 100 adults with high-functioning autism, 100 adults with another psychiatric disorder, and 100 adults without developmental disabilities and / or mental.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 324 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Validation of the French Adaptation of the Scale Aiding in the Diagnosis of the Autism Spectrum Disorders : Scale of Asperger Syndrome Diagnosis
Study Start Date : December 2011
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Patients with autism disorder
The RAADS-R scale is a self-administered questionnaire completed by the patient himself assisted by a clinician
Other: RAADS-R scale
This scale is a self-administered questionnaire completed by the person himself assisted by a clinician




Primary Outcome Measures :
  1. score at the RAADS-R scale [ Time Frame: 15 days ]
    The scale contains 80 items including 64 questions describe specific symptoms of autism spectrum disorders and 16 questions describe non-symptomatic behaviors



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Non-specific criteria
  • Collection of the informed consent (patient or legal representant)
  • Affiliation or recipient with the mode of social security
  • Current reading skills evaluated by completion of the fact sheet attached to the scale
  • Age limits to > 18 years and < 75 years

Specific criteria

  • Group of adult subjects with autism

    • Diagnosis of autism or Asperger syndrome established within the framework of a multidisciplinary evaluation (ADOS module 4 and/or ADI) using specific international classification criteria of rare diseases (CIM 10, DSM IV-R) (F84.0 et F84.5).
    • Intellectual efficiency estimated by means of a psychometric tool standardized (WAIS, WASI) greater than or equal to 85
    • Subjects not denying their symptoms
  • Group of adult subjects with other psychiatric

    • Diagnosis of an other psychiatric trouble established according to the specific international classification criteria of mental diseases (CIM 10, DSM IV).
    • absence of pervasive developmental disorder diagnosis
    • Subjects not denying their symptoms
  • Group of adult subjects not carriers of development and/or psychiatric disorders

Exclusion Criteria:

  • Women pregnant and Breast-feeding
  • Persons deprived of freedom by court order

Specific criteria

  • Group of adult subjects with autism

    • Refusal of participation
    • absence of autism or Asperger syndrome diagnosis
  • Group of adult subjects with other psychiatric

    • Refusal of participation
    • Pervasive developmental disorder diagnosis
  • Group of adult subjects not carriers of development and/or psychiatric disorders

    • Refusal of participation
    • Diagnosis of cognitive development or psychomotor disorder, diagnosis of retard mental and/or psychiatric disorder.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02826148


Sponsors and Collaborators
University Hospital, Montpellier
Fondation Orange
Investigators
Principal Investigator: Amaria BAGHDADLI, MD-PhD University Hospital, Montpellier

Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT02826148     History of Changes
Other Study ID Numbers: 8747
First Posted: July 7, 2016    Key Record Dates
Last Update Posted: July 7, 2016
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Asperger Syndrome
Neurodevelopmental Disorders
Mental Disorders